HEALTH
In a shocking development, the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) has announced the termination of three of its primary USAID agreements, putting critical HIV services at risk for thousands of children and pregnant women in Africa.
According to a statement released by EGPAF, the foundation received award termination notices despite previously securing approval to continue limited lifesaving work under the PEPFAR waiver from the U.S. Department of State. These agreements had been funding HIV programs in Lesotho, Eswatini, and Tanzania, where they served pregnant women, children, and families affected by HIV.
The termination means that EGPAF must immediately cease all activities and end sub-awards and contracts associated with these programs. The impact is expected to be devastating, as these projects currently support over 350,000 people on HIV treatment, including nearly 10,000 children and more than 10,000 HIV-positive pregnant women.
The decision comes at a critical time in the fight against HIV/AIDS, particularly in vulnerable communities where access to healthcare services remains limited. EGPAF warned that halting these programs would severely affect efforts to curb mother-to-child transmission and ensure treatment for HIV-positive children and expectant mothers.
While no official reason for the abrupt termination was provided in the statement, concerns are mounting over the future of HIV care in these regions. Advocates and public health officials are calling for urgent intervention to prevent the loss of crucial healthcare services.
EGPAF has been a global leader in pediatric HIV/AIDS care and prevention for decades, working to ensure that children and families receive the support they need to live healthy lives. The organization has expressed deep concern over the impact this decision will have on the communities it serves and is seeking alternative solutions to continue its mission.
With thousands of lives at stake, the global health community now faces a pressing challenge: how to sustain critical HIV treatment and prevention programs amid funding cuts and policy shifts.
